To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

GlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell ...

The drugmaker’s U.S. expansion comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% ...

GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...

GSK has announced that it will be expanding its immunology pipeline by acquiring a clinical-stage T cell-engager from ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

In a strategic move to enhance their immunology portfolio, GSK has announced an agreement to acquire experimental therapy ...

UK pharma major GSK looked set to close Wednesday’s trading around 3% lower. The London-based drugmaker earlier presented its ...

GSK is delivering consistent financial performance ... So with that, I'll now hand over to Luke and Deborah to talk you through our commercial performance. Thanks, Emma. Please turn to the ...

GSK plc (LON:GSK – Get Free Report) insider Jonathan Symonds bought 7,150 shares of the stock in a transaction dated ...